-
1.发明公开MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) 有权MODULATOREN DER PEROXISOM-PRIFIFERATOR-AKTIVIERTEN REZEPTOREN（PPAR）
公开(公告)号：EP1401434A1
公开(公告)日：2004-03-31
申请号：EP02746380.1
申请日：2002-05-24
发明人： GOSSETT, Lynn, Stacy , GREEN, Jonathan, Edward , HENRY, James, Robert , JONES, Winton, Dennis, Junior , MATTHEWS, Donald, Paul , SHEN, Quan, Rong , SMITH, Daryl, Lynn , VANCE, Jennifer, Ann , WARSHAWSKY, Alan, M. , GONZALEZ-GARCIA, Maria, Rosario
IPC分类号： A61K31/42
CPC分类号： C07D209/48 , C07C233/63 , C07C233/87 , C07C255/57 , C07C271/22 , C07C271/24 , C07C2601/04 , C07C2601/14 , C07D213/81 , C07D231/12 , C07D239/28 , C07D263/32 , C07D277/28 , C07D277/42 , C07D307/79 , C07D333/28 , C07D401/06 , C07D409/12 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D495/04
摘要： The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.
摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐，溶剂化物，水合物或立体异构体，其可用于治疗综合征X，II型糖尿病，高血糖症，高脂血症，肥胖，凝血病，高血压，动脉硬化等 与综合征X相关的疾病以及心血管疾病。
-
2.发明公开TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) 有权雄激素受体调节剂SUITABLE四氢咔唑衍生物
公开(公告)号：EP1902026A2
公开(公告)日：2008-03-26
申请号：EP06785258.2
申请日：2006-06-21
发明人： FALES, Kevin, Robert , GREEN, Jonathan, Edward , JADHAV, Prabhakar, Kondaji , MATTHEWS, Donald, Paul , NEEL, David, Andrew , SMITH, Edward, C R
IPC分类号： C07D209/88 , C07D491/04 , C07D403/04 , C07D417/04 , C07D401/04 , C07D417/14 , C07D401/14 , C07D417/06 , C07D409/06 , C07D401/06 , C07D413/04
CPC分类号： C07D401/14 , C07D209/88 , C07D401/04 , C07D401/06 , C07D409/06 , C07D413/04 , C07D417/04 , C07D417/06 , C07D417/14 , C07D491/04
摘要： The present invention provides a compound of the formula : Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of Formula (I).
-
公开(公告)号：EP1519915A2
公开(公告)日：2005-04-06
申请号：EP03810038.4
申请日：2003-06-13
发明人： COGHLAN, Michael, Joseph , GREEN, Jonathan, Edward , GRESE, Timothy, Alan , JADHAV, Prabhakar, Kondaji , MATTHEWS, Donald, Paul , STEINBERG, Mitchell, Irvin , FALES, Kevin, Robert , BELL, Michael, Gregory
IPC分类号： C07C311/08 , C07D221/16 , C07D235/14 , C07D313/12 , C07D401/06 , C07D403/06 , A61K31/18 , A61K31/553 , A61P7/10 , A61P9/12
CPC分类号： C07D213/16 , C07C22/04 , C07C22/08 , C07C25/24 , C07C33/38 , C07C39/17 , C07C39/23 , C07C39/42 , C07C43/215 , C07C43/225 , C07C43/23 , C07C47/548 , C07C47/57 , C07C49/835 , C07C69/00 , C07C69/618 , C07C69/65 , C07C205/06 , C07C205/34 , C07C205/35 , C07C211/28 , C07C211/32 , C07C211/45 , C07C215/76 , C07C217/84 , C07C233/07 , C07C233/65 , C07C233/84 , C07C235/16 , C07C251/40 , C07C251/48 , C07C255/50 , C07C261/04 , C07C271/14 , C07C275/28 , C07C307/10 , C07C311/03 , C07C311/08 , C07C311/09 , C07C311/16 , C07C311/20 , C07C311/21 , C07C311/29 , C07C317/14 , C07C317/32 , C07C321/28 , C07C323/49 , C07C2601/02 , C07C2603/32 , C07C2603/40 , C07C2603/78 , C07C2603/86 , C07D209/08 , C07D209/34 , C07D211/96 , C07D213/06 , C07D213/73 , C07D213/76 , C07D213/81 , C07D221/16 , C07D223/20 , C07D231/12 , C07D231/18 , C07D233/26 , C07D233/68 , C07D233/84 , C07D235/26 , C07D241/12 , C07D241/20 , C07D261/08 , C07D261/10 , C07D263/52 , C07D263/56 , C07D263/58 , C07D277/60 , C07D295/088 , C07D295/26 , C07D313/12 , C07D333/78 , C07D333/80 , C07D337/12 , C07D401/06 , C07D405/06 , C07D409/04 , C07D471/04 , C07D471/06 , C07D487/04 , C07D491/044
摘要： The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula (I), including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula (I).
-
4.发明授权TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) 有权雄激素受体调节剂SUITABLE四氢咔唑衍生物
公开(公告)号：EP1902026B1
公开(公告)日：2010-02-17
申请号：EP06785258.2
申请日：2006-06-21
发明人： FALES, Kevin, Robert , GREEN, Jonathan, Edward , JADHAV, Prabhakar, Kondaji , MATTHEWS, Donald, Paul , NEEL, David, Andrew , SMITH, Edward, C R
IPC分类号： C07D209/88 , C07D491/04 , C07D403/04 , C07D417/04 , C07D401/04 , C07D417/14 , C07D401/14 , C07D417/06 , C07D409/06 , C07D401/06 , C07D413/04
CPC分类号： C07D401/14 , C07D209/88 , C07D401/04 , C07D401/06 , C07D409/06 , C07D413/04 , C07D417/04 , C07D417/06 , C07D417/14 , C07D491/04
摘要： The present invention provides a compound of the formula : Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of Formula (I).
-
公开(公告)号：EP1597248A2
公开(公告)日：2005-11-23
申请号：EP04709806.6
申请日：2004-02-10
发明人： CONNER, Scott, Eugene , GOSSETT, Lynn, Stacy , GREEN, Jonathan, Edward , JONES, Winton, Dennis Jr. , MANTLO, Nathan, Bryan , MATTHEWS, Donald, Paul , MAYHUGH, Daniel, Ray , SMITH, Daryl, Lynn , VANCE, Jennifer, Ann , WANG, Xiaodong , WARSHAWSKY, Alan, M , WINNEROSKI, Leonard, Larry Jr. , XU, Yanping , ZHU, Guoxin
IPC分类号： C07D333/62 , C07D409/12 , C07C311/29 , C07C311/16 , C07D213/71 , C07D231/18 , C07D213/74 , C07D263/32 , C07D333/34 , C07D231/12 , C07D277/36 , C07D319/18 , C07D409/04 , C07D307/79
CPC分类号： C07D207/08 , A61K31/00 , A61K45/06 , C07C311/13 , C07C311/17 , C07C311/19 , C07C311/29 , C07C317/14 , C07C323/49 , C07C323/52 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D209/08 , C07D209/48 , C07D213/64 , C07D213/71 , C07D213/74 , C07D215/36 , C07D231/12 , C07D231/18 , C07D263/32 , C07D271/12 , C07D277/36 , C07D307/79 , C07D307/82 , C07D319/18 , C07D333/34 , C07D333/62 , C07D409/04 , C07D409/12 , C07D413/04 , A61K2300/00
摘要： The present invention is directed to a compound of Formula (I):, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
摘要翻译： 本发明涉及式（I）化合物及其药学上可接受的盐，溶剂化物，水合物或立体异构体，其可用于治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的病症，例如综合征X型 II型糖尿病，高血糖症，高脂血症，肥胖症，凝血病，高血压，动脉硬化以及与X综合症和心血管疾病相关的其它疾病。
-
6.发明授权TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS 有权TRICYCLISCHE STEROIDHORMONKERNREZEPTOR-MODULATOREN
公开(公告)号：EP1519915B1
公开(公告)日：2009-05-27
申请号：EP03810038.4
申请日：2003-06-13
发明人： COGHLAN, Michael, Joseph , GREEN, Jonathan, Edward , GRESE, Timothy, Alan , JADHAV, Prabhakar, Kondaji , MATTHEWS, Donald, Paul , STEINBERG, Mitchell, Irvin , FALES, Kevin, Robert , BELL, Michael, Gregory
IPC分类号： C07C311/08 , C07D221/16 , C07D235/14 , C07D313/12 , C07D401/06 , C07D403/06 , A61K31/18 , A61K31/553 , A61P7/10 , A61P9/12
CPC分类号： C07D213/16 , C07C22/04 , C07C22/08 , C07C25/24 , C07C33/38 , C07C39/17 , C07C39/23 , C07C39/42 , C07C43/215 , C07C43/225 , C07C43/23 , C07C47/548 , C07C47/57 , C07C49/835 , C07C69/00 , C07C69/618 , C07C69/65 , C07C205/06 , C07C205/34 , C07C205/35 , C07C211/28 , C07C211/32 , C07C211/45 , C07C215/76 , C07C217/84 , C07C233/07 , C07C233/65 , C07C233/84 , C07C235/16 , C07C251/40 , C07C251/48 , C07C255/50 , C07C261/04 , C07C271/14 , C07C275/28 , C07C307/10 , C07C311/03 , C07C311/08 , C07C311/09 , C07C311/16 , C07C311/20 , C07C311/21 , C07C311/29 , C07C317/14 , C07C317/32 , C07C321/28 , C07C323/49 , C07C2601/02 , C07C2603/32 , C07C2603/40 , C07C2603/78 , C07C2603/86 , C07D209/08 , C07D209/34 , C07D211/96 , C07D213/06 , C07D213/73 , C07D213/76 , C07D213/81 , C07D221/16 , C07D223/20 , C07D231/12 , C07D231/18 , C07D233/26 , C07D233/68 , C07D233/84 , C07D235/26 , C07D241/12 , C07D241/20 , C07D261/08 , C07D261/10 , C07D263/52 , C07D263/56 , C07D263/58 , C07D277/60 , C07D295/088 , C07D295/26 , C07D313/12 , C07D333/78 , C07D333/80 , C07D337/12 , C07D401/06 , C07D405/06 , C07D409/04 , C07D471/04 , C07D471/06 , C07D487/04 , C07D491/044
摘要： The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula (I), including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula (I).
摘要翻译： 本发明涉及治疗对类固醇激素核受体调节敏感的病理学障碍的方法，其包括向有需要的患者施用有效量的下式化合物或其药学上可接受的盐。 此外，本发明提供了新颖的式I的药物化合物，包括其药学上可接受的盐，以及包含作为活性成分的式I化合物的药物组合物。
-
公开(公告)号：EP1597248B1
公开(公告)日：2007-12-26
申请号：EP04709806.6
申请日：2004-02-10
发明人： CONNER, Scott, Eugene , GOSSETT, Lynn, Stacy , GREEN, Jonathan, Edward , JONES, Winton, Dennis Jr. , MANTLO, Nathan, Bryan , MATTHEWS, Donald, Paul , MAYHUGH, Daniel, Ray , SMITH, Daryl, Lynn , VANCE, Jennifer, Ann , WANG, Xiaodong , WARSHAWSKY, Alan, M , WINNEROSKI, Leonard, Larry Jr. , XU, Yanping , ZHU, Guoxin
IPC分类号： C07D333/62 , C07D409/12 , C07C311/29 , C07C311/16 , C07D213/71 , C07D231/18 , C07D213/74 , C07D263/32 , C07D333/34 , C07D231/12 , C07D277/36 , C07D319/18 , C07D409/04 , C07D307/79
CPC分类号： C07D207/08 , A61K31/00 , A61K45/06 , C07C311/13 , C07C311/17 , C07C311/19 , C07C311/29 , C07C317/14 , C07C323/49 , C07C323/52 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D209/08 , C07D209/48 , C07D213/64 , C07D213/71 , C07D213/74 , C07D215/36 , C07D231/12 , C07D231/18 , C07D263/32 , C07D271/12 , C07D277/36 , C07D307/79 , C07D307/82 , C07D319/18 , C07D333/34 , C07D333/62 , C07D409/04 , C07D409/12 , C07D413/04 , A61K2300/00
摘要： The present invention is directed to a compound of Formula (I):, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
-
公开(公告)号：EP1401434B1
公开(公告)日：2006-11-15
申请号：EP02746380.1
申请日：2002-05-24
发明人： GOSSETT, Lynn, Stacy , GREEN, Jonathan, Edward , HENRY, James, Robert , JONES, Winton, Dennis, Junior , MATTHEWS, Donald, Paul , SHEN, Quan, Rong , SMITH, Daryl, Lynn , VANCE, Jennifer, Ann , WARSHAWSKY, Alan, M. , GONZALEZ-GARCIA, Maria, Rosario
IPC分类号： A61K31/42 , C07D263/32 , A61P3/10
CPC分类号： C07D209/48 , C07C233/63 , C07C233/87 , C07C255/57 , C07C271/22 , C07C271/24 , C07C2601/04 , C07C2601/14 , C07D213/81 , C07D231/12 , C07D239/28 , C07D263/32 , C07D277/28 , C07D277/42 , C07D307/79 , C07D333/28 , C07D401/06 , C07D409/12 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D495/04
摘要： The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.023 秒)
